市场调查报告书
商品编码
1105809
阿柏西普中国市场(2022-2031)Investigation Report on China's Aflibercept Market 2022-2031 |
自2018年阿柏西普进入中国市场以来,2018年阿柏西普在中国的销售额达到830万元,2018-2021年的复合年增长率为206%,2021年将达到2.38亿元。 2021 年,受 COVID-19 疫情影响,复合年增长率放缓至 116%,但随着疫情好转,预计 2023 年至 2026 年将恢復并增长。
截至 2022 年 7 月,拜耳股份公司是中国阿柏西普市场上唯一的製造商。不过,在中国,很多药企都在仿製阿柏西普,仿製药有望在未来五年内进入中国市场,但短期内,拜耳的原研产品会受到较大影响,不考虑给予。
本报告研究和分析了中国的阿柏西普,提供市场规模、製造商分析和市场预测。
Aflibercept is an anti-VEGF drug, mainly used to treat neovascular age-related macular degeneration (wAMD), and other retinopathy caused by visual impairment. Aflibercept was jointly developed by Regeneron and Bayer. Regeneron has exclusive sales rights in the U.S. market, while Bayer obtains exclusive sales rights outside the U.S. Their Aflibercept, EYLEA was launched in China in 2018. By July 2022, Bayer AG is the only manufacturer in the Chinese Aflibercept market.
According to CRI's market research, after Aflibercept entered the Chinese market, the sales value of Aflibercept in China increased from CNY8.3 million in 2018 to CNY238 million in 2021. The annual growth rate in 2021 was 116%, which slowed down due to the COVID-19 epidemic. The CAGR of sales value of aflibercept in China is 206% from 2018 to 2021.
CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Aflibercept will have a recovery growth from 2023 to 2026. In addition, the sales will also increase due to market expansion. Currently, China has only approved two indications for Aflibercept, including treatment of wAMD and treatment of DME. However, Aflibercept had five approved indications globally, which means the sales will continue to grow as the number of indications expands. On the other hand, though the anti-VEGF ophthalmic drug market where Aflibercept belongs to accounts for the largest market share in the ophthalmology drug industry, the penetration rate for the anti-VEGF drug is still low. The penetration rate for the anti-VEGF drug is about 1% in China, while it exceeds 5% in the U.S. Since the market demand has not yet reached saturation, the sales will keep increasing. Besides, Aflibercept was included in the national medical insurance catalog at the beginning of 2020, so the price has been lowered, which reduces the burden on patients and will stimulate sales in the future.
Qilu Pharmaceutical, a local Chinese pharmaceutical company, received CDE (CENTER FOR DRUG EVALUATION, NMPA) approval for its marketing authorization application for aflibercept intravitreal injection in April 2022, which is the first biosimilar application for aflibercept in China.
According to CRI's market research, a number of other pharmaceutical companies in China are in the process of genericizing aflibercept, such as Clover Biopharmaceuticals' aflibercept intraocular injection, which is in the clinical phase of application, and Shandong Boan Biotechnology Co.
It is expected that the generic version of aflibercept will enter the Chinese market in the next five years, but it is unlikely to have a significant impact on Bayer's original drug in the short term.
Topics covered: